Oxford BioDynamics

Call Directions Website Contact the business

Oxford BioDynamics Today, OBD’s 24,000 sq ft headquarters in Oxford, UK, houses offices and state-of-the-art laboratory facilities. Follow us on Twitter.

Oxford BioDynamics (OBD) is a global biotech company advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases. OBD aims to help people face the most challenging health decisions with confidence and tackle the rising costs of healthcare with a portfolio of clinical tests and research tools based on its proprietary EpiSwitch® technology, uniquely capable of reproducibly translating 3D genome regulation for clinical application. The company’s flagship product, EpiSwitch CiRT (Checkpoint inhibitor Response Test), is a first-of-its-kind smart blood test for cancer patients that provides guidance on navigating the toughest challenges of immunotherapy like treatment planning, pseudo-progression, and adverse events. The company is partnering with CLIA-certified commercial labs to deliver these important tests into the hands of physicians to meet demand and help patients as quickly as possible. OBD’s commercial team has an office in Gaithersburg, MD, USA, and the company has an ISO-certified laboratory in Penang, Malaysia. OBD has participated in 40+ partnerships with pharma and leading institutions, including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital, and Mitsubishi Tanabe Pharma. The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostics, bioinformatic tools for 3D genomics, and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from 10,000+ samples in 30+ human diseases. OBD’s proprietary EpiSwitch technology maps this 3D architecture at scale, identifying abnormal configurations that can be used to diagnose patients or predict how someone may respond to a disease or treatment. For more information, please visit oxfordbiodynamics.com.

Heading to in Montréal (20–24 October)? Genomics has become extraordinarily good at generating genome sequences, and l...
16/10/2026

Heading to in Montréal (20–24 October)?

Genomics has become extraordinarily good at generating genome sequences, and less so at explaining them. Most disease-associated variation sits outside genes, and what those variants actually do is often an open question.

EpiSwitch® Orion predicts 3D regulatory genome architecture from whole-genome sequence, so you can ask new questions of your sequencing data.

CEO Rich Compton and CTO Dan Turner will be there to talk about Orion and the wider platform. To set up a meeting, message us through the 2026 Mobile App.

94percent.com ASHG - American Society of Human Genetics

100 days in as CEO of Oxford BioDynamics ( ), Rich Compton sat down with us to share what’s surprised him and where he s...
14/10/2026

100 days in as CEO of Oxford BioDynamics ( ), Rich Compton sat down with us to share what’s surprised him and where he sees headed.

His take: Genomics has become very good at reading genomes, but much less good at explaining them. After nearly 20 years of measuring how the genome folds, OBD is well placed to help close that gap, from Explorer in the lab to Orion, our computational platform, on existing genomic data.

Read the full conversation here 👉 https://obdx.co/wa5

94percent.com

01/10/2026

Garrett D Pohlman, M.D., presented “Urology Updates” at the Nebraska Academy of Family Physicians conference ( ), highlighting how is supporting earlier, high-fidelity prostate cancer evaluation in everyday practice across rural and metropolitan Nebraska. is proud to support physicians advancing prostate cancer detection across the state.

26/08/2026

🎙️ New episode of The Common Sense MD: "Beyond the PSA"

Dr. Garrett Pohlman joined Dr. Tom Rogers to unpack why an elevated PSA alone doesn't tell the full story, and how a routine EpiSwitch® PSE blood test can add clarity before biopsy or imaging decisions.

"It has been a game changer in my practice." — Garrett D Pohlman, M.D.

🎧 Listen now on Apple Podcasts, Spotify, or wherever you get your podcasts:
https://youtu.be/Z1vqyGPeHBg

Oxford BioDynamics
Performance Medicine

13/08/2026

Oxford BioDynamics partners with Dubai London Clinics and Hospitals to bring to the UAE, our first commercial partnership for the prostate cancer detection test in the Gulf region. Read more: https://mypse.co/d8t

In our latest In the Loop blog post, our CSO Dr Alexandre Akoulitchev discusses how 3D genomics was applied to ME/CFS....
12/08/2026

In our latest In the Loop blog post, our CSO Dr Alexandre Akoulitchev discusses how 3D genomics was applied to ME/CFS. The unique signature that we found distinguished severe chronic fatigue syndrome from healthy controls with 96% accuracy in a study published in the Journal of Translational Medicine.

Read more here: https://obdx.co/mqd

University of East Anglia (UEA)

We are pleased to announce that the company ( ) has raised £9.15 million with new and existing institutional and other i...
11/08/2026

We are pleased to announce that the company ( ) has raised £9.15 million with new and existing institutional and other investors, subject to shareholder approval. Read more here: https://obdx.co/f3x

Oxford BioDynamics has signed the first commercial agreement for EpiSwitch® Orion, its cloud-based discovery platform....
28/07/2026

Oxford BioDynamics has signed the first commercial agreement for EpiSwitch® Orion, its cloud-based discovery platform. transforms standard genome sequencing data, including legacy whole-genome datasets, into 3D regulatory intelligence, helping and partners move from statistical association to actionable target and biomarker discovery.

The agreement forms part of OPTIMISE, a research programme in funded by the UK Department of Health and Social Care - DHSC via the NIHR, and delivered in collaboration between the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences of the University of Oxford, the University of Glasgow, King's College London and Guy's and St Thomas' NHS Foundation Trust.

Read the announcement: https://obdx.co/op4

🩸 New on our In The Loop blog: "What I've Learned from More Than 500 PSE Orders."— We sat down for a Q&A with Garrett D ...
22/07/2026

🩸 New on our In The Loop blog: "What I've Learned from More Than 500 PSE Orders."

— We sat down for a Q&A with Garrett D Pohlman, M.D., a board-certified and one of the most experienced clinical users of .

He covers how the test fits into real-world evaluation, decision-making, what a Low vs High Likelihood result means for patients, billing, and how brings clarity when , , and clinical judgment don't fully agree.

"After using PSE more than 500 times, I believe its greatest value is helping to bring clarity."

👉 Read the full Q&A: https://mypse.co/qa500

94percent.com

We're pleased to announce the appointment of Richard Compton as Chief Executive Officer of Oxford BioDynamics ( ). A com...
30/06/2026

We're pleased to announce the appointment of Richard Compton as Chief Executive Officer of Oxford BioDynamics ( ). A commercial executive who has held senior leadership roles at Oxford Nanopore and Illumina, Richard will lead the next phase of OBD's development.

Read more: https://obdx.co/i8g

Address

3140 Rowan Place, John Smith Drive ARC
Oxford
OX42WB

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Telephone

+441865518910

Website

Alerts

Be the first to know and let us send you an email when Oxford BioDynamics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Oxford BioDynamics:

Shortcuts

Share

Category